In a randomized, placebo-controlled, double-blind phase II trial, 83 adult patients with FLT3-ITD mutated AML in CR after SCT were randomized to receive either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 43) or placebo (n = 40) for 24 months [70]. The gene discussed is FLT3; the disease is acute myeloid leukemia.